Regenxbio (RGNX) said Tuesday that it has closed its partnership with Japanese pharmaceutical and health food company Nippon Shinyaku.

The clinical-stage company said the agreement requires it and Nippon Shinyaku to develop and commercialize RGX-121 to treat patients with Hunter syndrome, and RGX-111 to treat Hurler syndrome in the US and Asia.

Regenxbio said RGX-121 is set to be the first gene therapy for Hunter syndrome, with FDA approval expected as early as late this year.